Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27197253 | 0.98 | ABL1 (0.49) | ABL1CDK9 | |
| SCHEMBL27197026 | 0.95 | ABL1 (0.50) | ABL1 | |
| SCHEMBL27196808 | 0.90 | ABL1 (0.48) | ABL1 | |
| SCHEMBL27197104 | 0.88 | DYRK1A (0.52) | ABL1 | |
| SCHEMBL29776474 | 0.88 | DYRK1A (0.52) | ABL1 | |
| SCHEMBL29094420 | 0.82 | NOTUM (0.39) | ABL1 | |
| SCHEMBL27197049 | 0.79 | PIK3C3 (0.39) | MEN1KMT2A | |
| SCHEMBL27196842 | 0.78 | ABL1 (0.42) | ABL1 | |
| SCHEMBL30595575 | 0.78 | ABL1 (0.42) | ABL1 | |
| SCHEMBL27196839 | 0.76 | ABL1 (0.52) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | claimed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | claimed |
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | ABL1 1664/4885POLB 2390/4885CDK9 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.